BRPI0514983A - combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca - Google Patents

combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca

Info

Publication number
BRPI0514983A
BRPI0514983A BRPI0514983-5A BRPI0514983A BRPI0514983A BR PI0514983 A BRPI0514983 A BR PI0514983A BR PI0514983 A BRPI0514983 A BR PI0514983A BR PI0514983 A BRPI0514983 A BR PI0514983A
Authority
BR
Brazil
Prior art keywords
combination
alpha
receptor agonist
delta ligand
treating migraine
Prior art date
Application number
BRPI0514983-5A
Other languages
English (en)
Inventor
Jayasena Hettiarachchi
Iradj Haji Mohamad Reza
Carolyn Rose Sikes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0419849.5A external-priority patent/GB0419849D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0514983A publication Critical patent/BRPI0514983A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMBINAçãO DE UM AGONISTA DO RECEPTOR 5-HT (1) E UM LIGANTE ALFA-2 -DELTA PAPA TRATAMENTO DA ENXAQUECA A presente invenção refere-se a uma combinação de 5 um agonista do receptor 5-HT~ 1B~, 5-HT~ lD~ ou 5-HT~ 1F~, e de um ligante alfa-2-delta. Uma tal combinação é de utilidade no tratamento da dor, particularmente, dor proveniente da enxaqueca.
BRPI0514983-5A 2004-09-07 2005-08-27 combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca BRPI0514983A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0419849.5A GB0419849D0 (en) 2004-09-07 2004-09-07 Pharmaceutical combination
US61460704P 2004-09-29 2004-09-29
PCT/IB2005/002684 WO2006027681A1 (en) 2004-09-07 2005-08-27 Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine

Publications (1)

Publication Number Publication Date
BRPI0514983A true BRPI0514983A (pt) 2008-07-01

Family

ID=35116045

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514983-5A BRPI0514983A (pt) 2004-09-07 2005-08-27 combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca

Country Status (6)

Country Link
EP (1) EP1791599A1 (pt)
JP (1) JP2008512436A (pt)
BR (1) BRPI0514983A (pt)
CA (1) CA2578990A1 (pt)
MX (1) MX2007002790A (pt)
WO (1) WO2006027681A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2337566A1 (en) * 2008-10-22 2011-06-29 Novartis AG Combinations for the treatment of migraine
BR112013009004B1 (pt) * 2010-10-15 2022-05-10 Contera Pharma Aps Uso de composição farmacêutica ou kit de partes compreendendo combinações de agonistas dereceptor de serotonina
IN2014DN09571A (pt) * 2012-04-18 2015-07-17 Contera Pharma Aps
CA3030089C (en) 2016-07-11 2024-04-23 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1093365A2 (en) * 1998-07-09 2001-04-25 Warner-Lambert Company Compositions comprising gaba analogs and a decongestant to relieve sinus headache pain
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations

Also Published As

Publication number Publication date
WO2006027681A1 (en) 2006-03-16
MX2007002790A (es) 2007-04-23
EP1791599A1 (en) 2007-06-06
CA2578990A1 (en) 2006-03-16
JP2008512436A (ja) 2008-04-24

Similar Documents

Publication Publication Date Title
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
DE602005016601D1 (de) 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
CR11107A (es) INDOLES SUSTITUIDOS EN LA POSICION 7 INHIBIDORES DE Mcl-1
TW200640867A (en) Pyridine-3-carboxamide derivatives as CB1 inverse agonists
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
MY144622A (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
TW200509924A (en) Compositions of cyclooxygenase-2 selective inhibitors and 5-HT 1B/1D agonists for the treatment and prevention of migraine
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NZ599464A (en) Combination therapies using hdac inhibitors
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
MX2008009579A (es) Metodo para el tratamiento de dolor neuropatico.
TW200740470A (en) Diclofenac formulations and methods of use
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
TW200716088A (en) Formulations and methods for treating amyloidosis
NO20092073L (no) Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
MXPA05013016A (es) Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/404 (2006.01), A61P 25/06 (2006.01), A61K